Next-generation ADCs, built on site-selective chemistry.
OPAL is a bioconjugation platform for building better-defined ADCs. By controlling exactly where and how payloads are attached, it delivers the homogeneity, stability, and streamlined production that next-generation therapeutics demand.
The technology
The OPAL platform
OPAL is a proprietary bioconjugation technology that installs payloads at defined sites on an antibody scaffold. By controlling exactly where and how many drug molecules are conjugated, OPAL eliminates the heterogeneous mixture of drug-to-antibody ratios (DAR) that limits conventional ADCs.
The result is a well-defined, homogeneous product with predictable pharmacokinetics, improved developability, and a clearer path from discovery to clinical candidate.
The platform
One chemistry, many capabilities
OPAL conjugation gives medicinal chemistry teams precise control over where, how much, and what is attached.
Site-selective
Conjugation is directed to a single, defined site on the antibody for truly homogeneous products.
Controlled DAR
Set and reliably reproduce the exact drug-to-antibody ratio your therapeutic requires.
Multi-payload
Attach distinct payloads to a single antibody to unlock combination and dual-mechanism ADCs.
Impact
Why it matters for ADC development
Conjugation heterogeneity is one of the biggest sources of unpredictability in ADC manufacturing. OPAL turns that variability into a controlled parameter.
Predictable PK
Controlled payload loading leads to more consistent pharmacokinetic profiles across batches.
Smoother scale-up
Low batch-to-batch variability supports robust process development and CMC timelines.
Off-the-shelf conjugation
Antibodies with certain common sequences or glycosylation profiles can be conjugated off-the-shelf with no further engineering
Building better ADCs
We believe streamlined, site-selective conjugation should be the foundation of every ADC, yielding conjugates with defined DAR by design, homogeneous by default, and reproducible at any scale.